Expertise in
14
conditions

Dr. Rohtesh Mehta

Hematology
UT MD Anderson Cancer Center
210 Ashville Ave # 408, 
Cary, NC 
Offers Telehealth
16 Years of Experience
Expertise in
14
conditions
UT MD Anderson Cancer Center
210 Ashville Ave # 408, 
Cary, NC 

Overview

Rohtesh Mehta is a Hematologist practicing medicine in Cary, North Carolina. He has been practicing medicine for over 16 years.

Dr. Mehta is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Graft Versus Host Disease (GvHD), Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 162 peer reviewed articles and participating in 7 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in PA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Premera
  • EPO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

UT MD Anderson Cancer Center
210 Ashville Ave # 408, Cary, NC 27518
Other Locations
Office
1515 Holcombe Blvd Unit 423, Houston, TX 77030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase I Study to Assess Safety of Selective JAK 1 Inhibitor, Itacitinib, in Patients With Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplant (HCT)
A Phase I Study to Assess Safety of Selective JAK 1 Inhibitor, Itacitinib, in Patients With Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplant (HCT)
Enrollment Status: Terminated
Publish Date: November 10, 2025
Intervention Type: Drug
Study Drug: Itacitinib
Study Phase: Phase 1
Acalabrutinib for Chronic Graft-Versus-Host Disease
Acalabrutinib for Chronic Graft-Versus-Host Disease
Enrollment Status: Active_not_recruiting
Publish Date: November 05, 2025
Intervention Type: Drug, Other
Study Drug: Acalabrutinib
Study Phase: Phase 2
Phase II Study of Umbilical Cord Blood-Derived Natural Killer Cells in Conjunction With Elotuzumab, Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant for Patients With Multiple Myeloma
Phase II Study of Umbilical Cord Blood-Derived Natural Killer Cells in Conjunction With Elotuzumab, Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant for Patients With Multiple Myeloma
Enrollment Status: Completed
Publish Date: May 09, 2025
Intervention Type: Drug, Other, Procedure, Biological
Study Drugs: Elotuzumab, Lenalidomide, Melphalan, Natural Killer Cell Therapy, Umbilical Cord Blood-Derived Lymphocyte Therapy
Study Phase: Phase 2
A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors
Enrollment Status: Terminated
Publish Date: July 15, 2022
Intervention Type: Drug, Biological
Study Drugs: IL-2, Fludarabine, Cyclophosphamide
Study Phase: Phase 1
View 3 Less Clinical Trials

162 Total Publications

HLA matching in contemporary haematopoietic cell transplantation: Recommendations from the EBMT Practice Harmonisation and Guidelines Committee.
HLA matching in contemporary haematopoietic cell transplantation: Recommendations from the EBMT Practice Harmonisation and Guidelines Committee.
Journal: Bone marrow transplantation
Published: April 14, 2026
Similar Doctors
Expertise in
39
conditions
Dr. Tapan Kadia
Hematology
Expertise in
39
conditions
Dr. Tapan Kadia
Hematology
Referral may be required

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (1050.4 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Tapan Kadia is a Hematologist practicing medicine in Cary, North Carolina. Dr. Kadia is highly rated in 39 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Prolymphocytic Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
33
conditions
Dr. Prithviraj Bose
Hematology
Expertise in
33
conditions
Dr. Prithviraj Bose
Hematology
Referral may be required

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (1050.4 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Prithviraj Bose is a Hematologist practicing medicine in Cary, North Carolina. Dr. Bose is highly rated in 33 conditions, according to our data. His clinical expertise encompasses Myelofibrosis, Essential Thrombocythemia, Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
30
conditions
Dr. Richard Champlin
Hematology
Expertise in
30
conditions
Dr. Richard Champlin
Hematology
Referral may be required

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (1050.4 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Richard Champlin is a Hematologist practicing medicine in Cary, North Carolina. Dr. Champlin is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Graft Versus Host Disease (GvHD), Leukemia, Bone Marrow Transplant, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Rohtesh Mehta

How do I make an appointment with Dr. Rohtesh Mehta?

You can book an appointment with Dr. Rohtesh Mehta by calling their office at 713-792-6161. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Rohtesh Mehta a top-rated expert for Graft Versus Host Disease (GvHD)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Rohtesh Mehta is classified as an Elite expert for Graft Versus Host Disease (GvHD), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Rohtesh Mehta specialize in?

While Dr. Rohtesh Mehta is a Hematology, they have specific expertise in Graft Versus Host Disease (GvHD), Acute Myeloid Leukemia (AML), and Bone Marrow Transplant. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Rohtesh Mehta participate in research or clinical trials?

Yes. Dr. Rohtesh Mehta has published 162 articles and abstracts on conditions like Graft Versus Host Disease (GvHD). You can view a list of Dr. Rohtesh Mehta's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Rohtesh Mehta accept my insurance?

Dr. Rohtesh Mehta accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 713-792-6161 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mehta's expertise for a condition
ConditionClose
View All 26 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile